|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | C.R. Bard, Inc. (NYSE: BCR), a manufacturer of vascular, urological and surgical products. |
|---|---|
| Transferring Party | Edward Lifesciences Corporation (NYSE: EW), a leading producer of advanced cardiovascular products. |
| Sector | Medical Devices |
| Date | December 7, 2007 |
| Analysis A significant strategic addition to Bard's portfolio of non-coronary stent and stent graft products. Enables Edwards to increase investment in its heart valve and critical care businesses. Retaining the business would have required substantial additional investment in order to become a market leader and operating losses were projected to continue despite sales growth. Deal value -- $140m (including $65m of potential milestone payments) on '07 sales of $30m (4.6x). | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |